Allergan Gets Patent Claims In Botox Suit Nixed At PTAB
By Matthew Bultman (March 29, 2017, 2:17 PM EDT) -- The Patent Trial and Appeal Board on Tuesday invalidated several claims in a pain treatment patent challenged by Allergan Inc., which was hit with infringement allegations in 2015 related to off-label uses of its blockbuster drug Botox.
Allergan sought inter partes review after Canadian company 1474791 Ontario Ltd. filed a lawsuit that claimed the drugmaker had violated its patent by coaching doctors to inject Botox into a patient's spinal muscles. Allergan argued that various claims in the patent were either anticipated or obvious.
The PTAB, in a final decision, agreed that the challenged claims were invalid.
"Petitioners have demonstrated by a...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!